首页> 外文期刊>World Journal of Surgery: Official Journal of the Societe Internationale de Chirurgie, Collegium Internationale Chirurgiae Digestivae, and of the International Association of Endocrine Surgeons >Efficacy and safety of preoperative lobar or segmental ablation via transarterial administration of ethiodol and ethanol mixture for treatment of hepatocellular carcinoma: clinical study.
【24h】

Efficacy and safety of preoperative lobar or segmental ablation via transarterial administration of ethiodol and ethanol mixture for treatment of hepatocellular carcinoma: clinical study.

机译:术前经叶动脉注射乙硫醇和乙醇混合物治疗肝细胞癌的有效性和安全性:临床研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Transarterial embolization (TAE) using various thrombotic substances for unresectable hepatocellular carcinoma (HCC) performed on many patients has resulted in a better survival rate. We evaluated the efficacy and clinical safety of using an Ethiodol-ethanol mixture as the embolizer for treatment of HCC and the possibility of a surgical approach for inoperable tumors after TAE. Twenty patients with HCC who underwent TAE and tumor resection were included in the study. Initially, eight had increased retention rate of indocyanine green dye via intravenous injection (0.5 mg/kg) at 15 minutes (ICGR15), and six had an insufficient residual volume that precluded them from undergoing tumor resection. TAE was performed by slowly infusing the mixture of Ethiodol and ethanol into the artery supplying the tumor until dual hepatic artery and portal vein embolization was achieved. Serum levels of alanine aminotransferase increased after embolization, but all biochemistry studies reverted to normal within 2 weeks. A decreased tumor size (n = 15), improved ICG (n = 8), and increased volume of the nonembolized lobe (n = 10) were noted. The operations performed were right lobectomy (n = 11), extended right lobectomy (n = 3), left lobectomy (n = 2), extended left lobectomy (n = 2), and wedge resection (n = 2), which included patients who did not want to undergo major hepatectomy. Complete tumor necrosis was found in seven cases. All patients survived with no associated complications. The 1-year survival rate was 95%. Transarterial Ethiodol and ethanol administration creating dual hepatic artery and portal vein embolization was a safe and efficacious method for treating HCC. It effectively decreases tumor size, causes compensatory hepatic hypertrophy, and improves the ICGR15, which allows a wider range of patients to undergo liver surgery and achieve better survival.
机译:对于许多患者,使用各种血栓性物质治疗无法切除的肝细胞癌(HCC)的经动脉栓塞(TAE)导致了更高的生存率。我们评估了使用Ethiodol-乙醇混合物作为栓塞剂治疗HCC的疗效和临床安全性,以及TAE后无法手术治疗肿瘤的手术方法的可能性。这项研究包括了20例接受了TAE和肿瘤切除术的HCC患者。最初,有15个患者在15分钟内通过静脉注射(0.5 mg / kg)(ICGR15)增加了吲哚菁绿染料的保留率,另外有6个患者的残留量不足,因此无法进行肿瘤切除。通过将Ethiodol和乙醇的混合物缓慢注入供应肿瘤的动脉中进行TAE,直到实现肝双动脉和门静脉栓塞。栓塞后血清丙氨酸转氨酶水平升高,但所有生化研究均在2周内恢复正常。注意到减小的肿瘤大小(n = 15),改善的ICG(n = 8)和增加的非栓塞性叶体积(n = 10)。所进行的手术包括右肺叶切除术(n = 11),右叶肺叶切除术(n = 3),左叶肺叶切除术(n = 2),左叶肺叶切除术(n = 2)和楔形切除术(n = 2),其中包括患者谁不想做大肝切除术。发现7例完全肿瘤坏死。所有患者均存活,无相关并发症。 1年生存率为95%。经动脉注射埃塞俄多和乙醇可产生双肝动脉和门静脉栓塞术,是治疗HCC的安全有效方法。它有效地减小了肿瘤的大小,引起代偿性肝肥大,并改善了ICGR15,使更广泛的患者可以接受肝脏手术并获得更好的生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号